Literature DB >> 29119054

MiR-216b functions as a tumor suppressor by targeting HMGB1-mediated JAK2/STAT3 signaling way in colorectal cancer.

Xiaoxiang Chen1,2, Xiangxiang Liu2, Bangshun He2, Yuqin Pan2, Huiling Sun2, Tao Xu2, Xiuxiu Hu2, Shukui Wang1,2.   

Abstract

MiR-216b is implicated in the development of multiple types of cancers, however, a role for miR-216b in colorectal cancer (CRC) remains elusive. The present study aimed to investigate the function and underlying mechanism of miR-216b in human CRC. In this study, we found miR-216b in CRC tissues and cell lines was markedly decreased compared with corresponding adjacent normal tissues (ANTs) and colonic mucosal epithelial cell line (FHC), and was obviously associated with the TNM stage, lymph node metastases, differentiation and poor overall survival (OS) (P<0.05). Furthermore, we demonstrated that miR-216b inhibited cell proliferation, migration, invasion and angiogenesis by targeting HMGB1 which was highly expressed in CRC. Additionally, we proved that miR-216b promoted the development and progression of CRC, at least partially through HMGB1-mediated JAK2/STAT3 pathway. Lastly, we showed that plasma miR-216b expression was reduced in CRC when compared to healthy controls and might be a potential diagnostic biomarker for CRC. The findings indicated that miR-216b might function as a suppressor in CRC and could serve as a promising diagnostic and prognostic biomarker for CRC.

Entities:  

Keywords:  HMGB1; JAK2/STAT3; MiR-216b; colorectal cancer (CRC)

Year:  2017        PMID: 29119054      PMCID: PMC5665852     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  49 in total

Review 1.  New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal.

Authors:  S Müller; P Scaffidi; B Degryse; T Bonaldi; L Ronfani; A Agresti; M Beltrame; M E Bianchi
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

2.  MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.

Authors:  Ying Wang; Po Xu; Jun Yao; Ruina Yang; Zhenguo Shi; Xiaojuan Zhu; Xiaoshan Feng; Shegan Gao
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

3.  High-mobility group box 1 protein activating nuclear factor-κB to upregulate vascular endothelial growth factor C is involved in lymphangiogenesis and lymphatic node metastasis in colon cancer.

Authors:  Yan Li; Jianming He; Daping Zhong; Jianjun Li; Houjie Liang
Journal:  J Int Med Res       Date:  2015-05-22       Impact factor: 1.671

4.  miR-320a regulates high mobility group box 1 expression and inhibits invasion and metastasis in hepatocellular carcinoma.

Authors:  Guixiang Lv; Mingjuan Wu; Meijie Wang; Xiaochen Jiang; Jingli Du; Kaili Zhang; Dongliang Li; Ning Ma; Yahui Peng; Lujing Wang; Lingyun Zhou; Weiming Zhao; Yufei Jiao; Xu Gao; Zheng Hu
Journal:  Liver Int       Date:  2017-04-11       Impact factor: 5.828

5.  Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.

Authors:  Haining Yang; Zeyana Rivera; Sandro Jube; Masaki Nasu; Pietro Bertino; Chandra Goparaju; Guido Franzoso; Michael T Lotze; Thomas Krausz; Harvey I Pass; Marco E Bianchi; Michele Carbone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

6.  Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.

Authors:  Oliver J Stoetzer; Debora M I Fersching; Christoph Salat; Oliver Steinkohl; Christian J Gabka; Ulrich Hamann; Michael Braun; Axel-Mario Feller; Volker Heinemann; Barbara Siegele; Dorothea Nagel; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2012-09-15

7.  Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma.

Authors:  Xingjun Yao; Gang Zhao; Hongfa Yang; Xinyu Hong; Li Bie; Guojin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-07       Impact factor: 4.553

Review 8.  High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.

Authors:  Marco E Bianchi; Angelo A Manfredi
Journal:  Immunol Rev       Date:  2007-12       Impact factor: 12.988

9.  MicroRNA-27b suppresses tumor progression by regulating ARFGEF1 and focal adhesion signaling.

Authors:  Rei Matsuyama; Daisuke Okuzaki; Masato Okada; Chitose Oneyama
Journal:  Cancer Sci       Date:  2015-11-18       Impact factor: 6.716

10.  MiR-142 inhibits the development of cervical cancer by targeting HMGB1.

Authors:  Daqiong Jiang; Huiyan Wang; Zhuyan Li; Zhen Li; Xin Chen; Hongbing Cai
Journal:  Oncotarget       Date:  2017-01-17
View more
  20 in total

1.  ResolvinD1 attenuates high-mobility group box 1-induced epithelial-to-mesenchymal transition in nasopharyngeal carcinoma cells.

Authors:  Pingli Yang; Shan Chen; Gang Zhong; Yan Wang; Weijia Kong; Yanjun Wang
Journal:  Exp Biol Med (Maywood)       Date:  2019-11-01

2.  [Dihydromyricetin inhibits proliferation and migration of gastric cancer cells through regulating Akt/STAT3 signaling pathways and HMGB1 expression].

Authors:  Shengnan Wang; Fei Ge; Tianyu Cai; Shimei Qi; Zhilin Qi
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

Review 3.  HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.

Authors:  Kim Jun Cheng; Mohammed Abdullah Alshawsh; Elsa Haniffah Mejia Mohamed; Surendran Thavagnanam; Ajantha Sinniah; Zaridatul Aini Ibrahim
Journal:  Cell Oncol (Dordr)       Date:  2019-11-01       Impact factor: 6.730

4.  miR-125a-5p suppresses colorectal cancer progression by targeting VEGFA.

Authors:  Xuehua Yang; Jianwei Qiu; Haifeng Kang; Yaming Wang; Junbo Qian
Journal:  Cancer Manag Res       Date:  2018-11-16       Impact factor: 3.989

5.  lncRNA DSCAM-AS1 downregulates miR-216b to promote the migration and invasion of colorectal adenocarcinoma cells.

Authors:  Fei Liu; Jianhui Jia; Liping Sun; Qingrui Yu; Hongyan Duan; Dexin Jiao; Zhiqiang Gong; Shendong Zhu; Kexin Jiang; Yijiang He; Liping Chen; Yanni Zhang; Han Sun
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

6.  MiR-216b suppresses colorectal cancer proliferation, migration, and invasion by targeting SRPK1.

Authors:  Yanfen Yao; Qiaorong Li; Hong Wang
Journal:  Onco Targets Ther       Date:  2018-03-23       Impact factor: 4.147

7.  Single Nucleotide Polymorphisms in HMGB1 Correlate with Lung Cancer Risk in the Northeast Chinese Han Population.

Authors:  Min Jiang; Xuelian Li; Xiaowei Quan; Xiaoying Li; Baosen Zhou
Journal:  Molecules       Date:  2018-04-04       Impact factor: 4.411

Review 8.  Epigenetic Regulation by lncRNAs: An Overview Focused on UCA1 in Colorectal Cancer.

Authors:  Bernadette Neve; Nicolas Jonckheere; Audrey Vincent; Isabelle Van Seuningen
Journal:  Cancers (Basel)       Date:  2018-11-14       Impact factor: 6.639

9.  MiR-3150b-3p inhibits the progression of colorectal cancer cells via targeting GOLPH3.

Authors:  Weiqing Zhang; Xiaoyan Chen; Junzhi Jia
Journal:  J Investig Med       Date:  2019-11-02       Impact factor: 2.895

10.  RETRACTED: METTL14 Suppresses CRC Progression via Regulating N6-Methyladenosine-Dependent Primary miR-375 Processing

Authors:  Xiaoxiang Chen; Mu Xu; Xueni Xu; Kaixuan Zeng; Xiangxiang Liu; Li Sun; Bei Pan; Bangshun He; Yuqin Pan; Huiling Sun; Xinyi Xia; Shukui Wang
Journal:  Mol Ther       Date:  2019-11-20       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.